Breast Cancer Drug Repurposing a Tool for a Challenging Disease

Malik, Jonaid Ahmad; Jan, Rafia; Ahmed, Sakeel; Anwar, Sirajudheen

doi:10.5772/intechopen.101378

Cited by 5 publications

(4 citation statements)

References 90 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, miRNA profiling and comprehension are crucial for BC diagnosis, subtyping, prognosis, and recurrence and treatment response prediction. Additionally, numerous anti-oncomiRs and tumor suppressor miRNAs have been created as treatments that can be used alone or in conjunction with conventional BC therapy [ 129 ]. They can be discharged in liquid biopsy samples including urine, blood, milk, and other physiological fluids.…”

Section: Future Prospectsmentioning

confidence: 99%

Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment

Shinde

Ahmed

Malik

et al. 2023

Biology

View full text Add to dashboard Cite

The death rate from breast cancer (BC) has dropped due to early detection and sophisticated therapeutic options, yet drug resistance and relapse remain barriers to effective, systematic treatment. Multiple mechanisms underlying miRNAs appear crucial in practically every aspect of cancer progression, including carcinogenesis, metastasis, and drug resistance, as evidenced by the elucidation of drug resistance. Non-coding RNAs called microRNAs (miRNAs) attach to complementary messenger RNAs and degrade them to inhibit the expression and translation to proteins. Evidence suggests that miRNAs play a vital role in developing numerous diseases, including cancer. They affect genes critical for cellular differentiation, proliferation, apoptosis, and metabolism. Recently studies have demonstrated that miRNAs serve as valuable biomarkers for BC. The contrast in the expression of miRNAs in normal tissue cells and tumors suggest that miRNAs are involved in breast cancer. The important aspect behind cancer etiology is the deregulation of miRNAs that can specifically influence cellular physiology. The main objective of this review is to emphasize the role and therapeutic capacity of tumor suppressor miRNAs in BC and the advancement in the delivery system that can deliver miRNAs specifically to cancerous cells. Various approaches are used to deliver these miRNAs to the cancer cells with the help of carrier molecules, like nanoparticles, poly D, L-lactic-co-glycolic acid (PLGA) particles, PEI polymers, modified extracellular vesicles, dendrimers, and liposomes. Additionally, we discuss advanced strategies of TS miRNA delivery techniques such as viral delivery, self-assembled RNA-triple-helix hydrogel drug delivery systems, and hyaluronic acid/protamine sulfate inter-polyelectrolyte complexes. Subsequently, we discuss challenges and prospects on TS miRNA therapeutic delivery in BC management so that miRNAs will become a routine technique in developing individualized patient profiles.

show abstract

Section: Future Prospectsmentioning

confidence: 99%

Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment

Shinde

Ahmed

Malik

et al. 2023

Biology

View full text Add to dashboard Cite

show abstract

“…In such cases, drug repurposing or reprofiling can play a vital role by reducing developmental drug costs and manufacturing time. For example, Aspirin, Metformin, Niclosamide, Itraconazole, and Simvastatin are some of the non-oncological drugs that have been repurposed for BC treatment [153].…”

Section: Drug Repurposing and Drug Development By Using Proteomicsmentioning

confidence: 99%

Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment

Behera,

Bisht,

Giri

et al. 2023

Proteomics Clinical Apps

View full text Add to dashboard Cite

Breast cancer, a multi‐networking heterogeneous disease, has emerged as a serious impediment to progress in clinical oncology. Although technological advancements and emerging cancer research studies have mitigated breast cancer lethality, a precision cancer‐oriented solution has not been achieved. Thus, this review will persuade the acquiescence of proteomics‐based diagnostic and therapeutic options in breast cancer management. Recently, the evidence of breast cancer health surveillance through imaging proteomics, single‐cell proteomics, interactomics, and post‐translational modification (PTM) tracking, to construct proteome maps and proteotyping for stage‐specific and sample‐specific cancer subtyping have outperformed conventional ways of dealing with breast cancer by increasing diagnostic efficiency, prognostic value, and predictive response. Additionally, the paradigm shift in applied proteomics for designing a chemotherapy regimen to identify novel drug targets with minor adverse effects has been elaborated. Finally, the potential of proteomics in alleviating the occurrence of chemoresistance and enhancing reprofiled drugs' effectiveness to combat therapeutic obstacles has been discussed. Owing to the enormous potential of proteomics techniques, the clinical recognition of proteomics in breast cancer management can be achievable and therapeutic intricacies can be surmountable.

show abstract

“…Many noteworthy examples have revolutionized the drug discovery process by drug repurposing. Several drugs already approved for other ailments are also approved for cancer. , Although the success rate may not be high, research is about finding novel ideas and rediscovering things to serve humanity. There are many examples where drug repurposing was successful but seldom passed in clinical or preclinical phases.…”

Section: Repurposing Of Cvs Drugs For Prostate Cancer Treatmentmentioning

confidence: 99%

Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

Prostate cancer (PCA), the most common cancer in men, accounted for 1.3 million new incidences in 2018. An increase in incidences is an issue of concern that should be addressed. Of all the reported prostate cancers, 85% were detected in stages III and IV, making them difficult to treat. Conventional drugs gradually lose their efficacy due to the developed resistance against them, thus requiring newer therapeutic agents to be used as monotherapy or combination. Recent research regarding treatment options has attained remarkable speed and development. Therefore, in this context, drug repurposing comes into the picture, which is defined as the "investigation of the off-patent, approved and marketed drugs for a novel therapeutic indication" which saves at least 30% of the time and cost, reducing the cost of treatment for patients, which usually runs high in cancer patients. The anticancer property of cardiac glycosides in cancers was tested in the early 1980s. The trend then shifts toward treating prostate cancer by repurposing other cardiovascular drugs. The current review mainly emphasizes the advantageous antiprostate cancer profile of conventional CVS drugs like cardiac glycosides, RAAS inhibitors, statins, heparin, and beta-blockers with underlying mechanisms.

show abstract

Breast Cancer Drug Repurposing a Tool for a Challenging Disease

Cited by 5 publications

References 90 publications

Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment

Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment

Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment

Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer

Contact Info

Product

Resources

About